Oric Pharmaceuticals
Siyu Liu is a skilled research professional with a background in pharmaceutical sciences and drug delivery systems. Currently serving as a Research Associate at ORIC Pharmaceuticals Inc. since May 2023, Siyu previously held the position of Senior Research Associate at Tessera Therapeutics from October 2020 to 2022 and was a Research Associate at Dicerna Pharmaceuticals, Inc. from February 2019 to October 2020. An internship at PanTher Therapeutics in early 2018 provided foundational experience. Siyu Liu earned a Master's degree in Drug Targeting and Delivering Systems from Northeastern University and a Bachelor's degree in Pharmaceutical Sciences from Shenyang Pharmaceutical University.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.